1. Home
  2. STG vs ATYR Comparison

STG vs ATYR Comparison

Compare STG & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunlands Technology Group

STG

Sunlands Technology Group

HOLD

Current Price

$4.65

Market Cap

66.3M

Sector

Real Estate

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$1.04

Market Cap

69.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STG
ATYR
Founded
2003
2005
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.3M
69.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
STG
ATYR
Price
$4.65
$1.04
Analyst Decision
Hold
Analyst Count
0
8
Target Price
N/A
$4.20
AVG Volume (30 Days)
2.3K
2.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18,728.62
P/E Ratio
$1.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$0.64
52 Week High
$15.00
$7.29

Technical Indicators

Market Signals
Indicator
STG
ATYR
Relative Strength Index (RSI) 37.63 67.05
Support Level $4.35 $0.82
Resistance Level $5.19 $1.11
Average True Range (ATR) 0.17 0.10
MACD -0.02 0.02
Stochastic Oscillator 35.71 76.65

Price Performance

Historical Comparison
STG
ATYR

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: